Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dabouis

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancerJ Klastersky, J P Sculier, F Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, J Klastersky, V Giner, et al.
Cancer|November 1, 1994
Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesotheliomaC Boutin, E Nussbaum, I Monnet, et al.
Cancer|April 1, 1990
Evaluation of squamous cell carcinoma antigen as a new marker for lung cancerJ J Body, J P Sculier, N Raymakers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working PartyJ P Sculier, M Paesmans, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working PartyJ Klastersky, J P Sculier, F Ries, et al.
Cancer Treatment Reports|February 1, 1987
Phase II trial of vindesine in malignant pleural mesotheliomaC Boutin, M Irisson, J C Guérin, et al.
Revue Des Maladies Respiratoires|January 1, 1994
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]J P Sculier, M Paesmans, G Bureau, et al.
Henry Ford Hospital Medical Journal|January 1, 1989
A preliminary evaluation of calcitonin and PDN-21 as tumor markers for lung cancer. EORTC Lung Cancer Working PartyJ J Body, J C Dumon, J P Sculier, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 1998
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working PartyM Paesmans, J P Sculier, P Libert, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|December 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancerJ Klastersky, J P Sculier, F Ries, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working PartyJ P Sculier, J Klastersky, V Giner, et al.
Cancer|November 1, 1994
Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesotheliomaC Boutin, E Nussbaum, I Monnet, et al.
Cancer|April 1, 1990
Evaluation of squamous cell carcinoma antigen as a new marker for lung cancerJ J Body, J P Sculier, N Raymakers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working PartyJ P Sculier, M Paesmans, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1994
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working PartyJ Klastersky, J P Sculier, F Ries, et al.
Cancer Treatment Reports|February 1, 1987
Phase II trial of vindesine in malignant pleural mesotheliomaC Boutin, M Irisson, J C Guérin, et al.
Revue Des Maladies Respiratoires|January 1, 1994
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]J P Sculier, M Paesmans, G Bureau, et al.
Henry Ford Hospital Medical Journal|January 1, 1989
A preliminary evaluation of calcitonin and PDN-21 as tumor markers for lung cancer. EORTC Lung Cancer Working PartyJ J Body, J C Dumon, J P Sculier, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 1998
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working PartyM Paesmans, J P Sculier, P Libert, et al.
Pageof 6